A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jul 2018

At a glance

  • Drugs Apremilast (Primary)
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms PALACE-2
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 16 Jun 2018 Results of subgroup analysis assessing long-term exposure of patients who failed to achieve ACR20 at week 104 from three studies (PALACE-1, -2 and -3) presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 16 Jun 2018 Results of a pooled analysis of PALACE 1, 2 and 3 studies assessing long-term efficacy and safety of Apremilast treatment (n=1493) presented at the 19th Annual Congress of the European League Against Rheumatism
    • 16 Jun 2018 Results of pooled analysis (PALACE 1-3) presented at the 19th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top